See more : Fruta Fruta Inc. (2586.T) Income Statement Analysis – Financial Results
Complete financial analysis of NRx Pharmaceuticals, Inc. (NRXP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NRx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Oculus VisionTech, Inc. (OVT.V) Income Statement Analysis – Financial Results
- Netflix, Inc. (NFLX) Income Statement Analysis – Financial Results
- RDE, Inc. (GIFT) Income Statement Analysis – Financial Results
- Millrock Resources Inc. (0V6Y.L) Income Statement Analysis – Financial Results
- Eslead Corporation (8877.T) Income Statement Analysis – Financial Results
NRx Pharmaceuticals, Inc. (NRXP)
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 4.00K | 2.00K | 907.41K | 0.00 | 1.01M | 0.00 |
| Gross Profit | -5.00K | -4.00K | -2.00K | -907.41K | 0.00 | -1.01M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.37M | 17.03M | 20.26M | 10.63M | 3.50K | 0.00 | 0.00 |
| General & Administrative | 14.22M | 27.37M | 74.94M | 11.44M | 2.77K | 0.00 | 0.00 |
| Selling & Marketing | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.21M | 27.37M | 74.94M | 11.44M | 2.77K | 1.01M | 0.00 |
| Other Expenses | 0.00 | -505.00K | -771.00K | -10.16M | 713.19K | 1.01M | 0.00 |
| Operating Expenses | 27.58M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Cost & Expenses | 27.59M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Interest Income | 494.00K | 249.00K | 18.00 | 56.00 | 1.21M | 1.09M | 0.00 |
| Interest Expense | 120.00K | 0.00 | 18.00K | 56.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.00K | 4.00K | 2.00K | 2.00K | 0.86 | 1.09M | 52.52K |
| EBITDA | -30.03M | -39.75M | -93.04M | -51.72M | -713.19K | 82.41K | -105.04K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -27.59M | -44.40M | -115.80M | -51.39M | -6.26K | -1.01M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.57M | 4.58M | 22.73M | -39.88M | 1.21M | 1.09M | -105.03K |
| Income Before Tax | -30.16M | -39.82M | -93.06M | -51.78M | 492.63K | 82.41K | -105.03K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.00K | -4.58M | -21.35M | -39.43M | 84.21K | 16.31K | 0.00 |
| Net Income | -30.15M | -35.24M | -71.72M | -12.35M | 408.43K | 66.10K | -105.03K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| EPS Diluted | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| Weighted Avg Shares Out | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
| Weighted Avg Shares Out (Dil) | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)
FDA response highlights the importance of addressing suicidal depression in adolescents age 9-17 Alignment on initial Pediatric Study Plan (iPSP) is a gating requirement for the upcoming filing of an NRX-100 New Drug Application (NDA) for suicidal depression NRx remains...
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff
Petition for a temporary restraining order brought by Streeterville Capital, LLC seeking injunctive relief to prevent spinoff of 49% of HOPE Therapeutics shares to current NRx Shareholders has been denied by Utah arbitrator. Petition by Streeterville Capital, LLC seeking injunctive relief to...
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
Potential paths to revenue and profitability in 2025 RADNOR, Pa. , July 1, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new Shareholder Update Letter on...
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing
New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 2024, based on two positive trials 1 2 and Breakthrough Therapy Designation. Potential revenue in 2025 NDA for NRX-100 (IV ketamine) in...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced that management will participate in the H.C.
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors
Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology Retired at a rank that is the civilian equivalent of a senior flag officer from the United States Navy RADNOR, Pa. , June 18,...
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression and suicidality Presenters from 3 open label...
NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression
Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior" NRX-101 demonstrated a similar antidepressant effect (MADRS reduction ~50%) compared to lurasidone, the Standard of Care...
NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Company's Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard...
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor for an initial $7.5 million note, subject to common closing requirements,...
Source: https://incomestatements.info
Category: Stock Reports